Achiko AG – Investor Briefing

Rhea-AI Summary

Achiko AG (OTCQB: ACHKF, SIX: ACHI) invites investors to a moderated investor call on July 8, 2022, at 8:30 am EDT. A PowerPoint presentation will be available prior to the call. Achiko is known for developing disruptive diagnostic solutions, with its leading product being a rapid Covid-19 test and companion app launched in Indonesia. The company also plans to submit an application for CE Mark approval in Europe in 2022.

Positive

• Achiko has launched a rapid Covid-19 test and companion app in Indonesia.
• The company plans to apply for CE Mark approval in Europe in 2022, potentially expanding its market.

Negative

• None.

ZURICH, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF, SIX: ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), would like to invite investors and shareholders to a moderated investor call.

A PowerPoint presentation will be available prior to the call and published on the Achiko AG website.

Details are as follows:

	Date:	July 8, 2022
	Time:	8:30 am EDT / 2:30 pm CEST
	Format:	Zoom Call
	Presenter:	Mr. Steven Goh, CEO of Achiko AG
	Meeting link:	https://us02web.zoom.us/j/6191486127?pwd=VWJYa0VmWFV3OTBiL1RDd0o5NjR2dz09
	Meeting ID:	619 148 6127
	Passcode:	888
	Find your local number: https://us02web.zoom.us/u/knHHcenwR

ABOUT ACHIKO AG 
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and an application for CE Mark approval in Europe will be submitted in 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX^TM and companion health apps via its digital mobile health technology division, Teman Sehat^TM. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:

ACHIKO AG
Investor Relations 
E: ir@achiko.com  

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch  
T: +41 44 266 67 67

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties, and other factors, which could cause the actual results, financial condition, performance, or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

FAQ

What is the date of Achiko AG's investor call?

Achiko AG's investor call is scheduled for July 8, 2022.

What time is the Achiko AG investor call?

The investor call will take place at 8:30 am EDT / 2:30 pm CEST.

How can I join the Achiko AG investor call?

You can join the Achiko AG investor call via Zoom at this link: https://us02web.zoom.us/j/6191486127?pwd=VWJYa0VmWFV3OTBiL1RDd0o5NjR2dz09.

What is Achiko AG's lead product?

Achiko AG's lead product is a rapid Covid-19 test with a companion app.

Where was Achiko AG's Covid-19 test launched?

The Covid-19 test was launched in Indonesia.

What are Achiko AG's plans for CE Mark approval?

Achiko AG intends to submit an application for CE Mark approval in Europe in 2022.